272 related articles for article (PubMed ID: 31722862)
21. Impact of Low-level Viremia on Treatment Outcomes During ART - Is it Time to Revise the Definition of Virological Failure?
Poveda E; Crespo M
AIDS Rev; 2018; 20(1):71-72. PubMed ID: 29628513
[TBL] [Abstract][Full Text] [Related]
22. The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure.
Davies MA; Boulle A; Technau K; Eley B; Moultrie H; Rabie H; Garone D; Giddy J; Wood R; Egger M; Keiser O;
Trop Med Int Health; 2012 Nov; 17(11):1386-90. PubMed ID: 22974345
[TBL] [Abstract][Full Text] [Related]
23. Low-Level Viremia Predicts Virological Failure in HIV-Infected Omani Patients Receiving Antiretroviral Therapy.
Gaifer Z; Boulassel MR
J Int Assoc Provid AIDS Care; 2020; 19():2325958220979817. PubMed ID: 33372823
[TBL] [Abstract][Full Text] [Related]
24. HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study.
Afrane AKA; Goka BQ; Renner L; Yawson AE; Alhassan Y; Owiafe SN; Agyeman S; Sagoe KWC; Kwara A
BMC Infect Dis; 2021 Aug; 21(1):731. PubMed ID: 34340689
[TBL] [Abstract][Full Text] [Related]
25. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.
Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
AIDS; 2002 May; 16(7):1039-44. PubMed ID: 11953470
[TBL] [Abstract][Full Text] [Related]
26. Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean?
Lee KJ; Shingadia D; Pillay D; Walker AS; Riordan A; Menson E; Duong T; Tudor-Williams G; Gibb DM;
Antivir Ther; 2007; 12(6):949-56. PubMed ID: 17926649
[TBL] [Abstract][Full Text] [Related]
27. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.
Easterbrook PJ; Ives N; Waters A; Mullen J; O'Shea S; Peters B; Gazzard BG
AIDS; 2002 Jul; 16(11):1521-7. PubMed ID: 12131190
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Immunological and Virological Outcomes in Children Receiving Highly Active Antiretroviral Therapy at Hawassa University College of Medicine and Health Sciences, Southern Ethiopia.
Fenta DA; Wube TB; Nuru MM
J Immunol Res; 2021; 2021():2498025. PubMed ID: 33928167
[TBL] [Abstract][Full Text] [Related]
29. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
[TBL] [Abstract][Full Text] [Related]
30. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
[TBL] [Abstract][Full Text] [Related]
31. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
[TBL] [Abstract][Full Text] [Related]
32. Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value.
Oliveira R; Krauss M; Essama-Bibi S; Hofer C; Robert Harris D; Tiraboschi A; de Souza R; Marques H; Succi R; Abreu T; Della Negra M; Hazra R; Mofenson LM; Siberry GK;
Clin Infect Dis; 2010 Dec; 51(11):1325-33. PubMed ID: 21039218
[TBL] [Abstract][Full Text] [Related]
33. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study.
Zoufaly A; Fillekes Q; Hammerl R; Nassimi N; Jochum J; Drexler JF; Awasom CN; Sunjoh F; Burchard GD; Burger DM; van Lunzen J; Feldt T
Antivir Ther; 2013; 18(5):681-90. PubMed ID: 23502762
[TBL] [Abstract][Full Text] [Related]
35. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
[TBL] [Abstract][Full Text] [Related]
36. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
37. Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali.
Sylla M; Dolo O; Maiga AI; Traore FT; Coulibaly YA; Togo J; Fofana DB; Dicko-Traore F; Doumbia S; Orsega S; Diallo S; Murphy RL; Calvez V; Marcelin AG
Arch Pediatr; 2019 Jul; 26(5):254-258. PubMed ID: 31307909
[TBL] [Abstract][Full Text] [Related]
38. Genotype-Informed Versus Empiric Management Of VirEmia (GIVE MOVE): study protocol of an open-label randomised clinical trial in children and adolescents living with HIV in Lesotho and Tanzania.
Brown JA; Ringera I; Luoga E; Cheleboi M; Kimera N; Muhairwe J; Kayembe BP; Molapo Hlasoa M; Kabundi L; Yav CWD; Mothobi B; Thahane L; Amstutz A; Bachmann N; Mollel GJ; Bresser M; Glass TR; Paris DH; Klimkait T; Weisser M; Labhardt ND
BMC Infect Dis; 2020 Oct; 20(1):773. PubMed ID: 33076866
[TBL] [Abstract][Full Text] [Related]
39. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
[TBL] [Abstract][Full Text] [Related]
40. Brief Report: Lopinavir Hair Concentrations Are the Strongest Predictor of Viremia in HIV-Infected Asian Children and Adolescents on Second-Line Antiretroviral Therapy.
Pintye J; Bacchetti P; Teeraananchai S; Kerr S; Prasitsuebsai W; Singtoroj T; Kuncze K; Louie A; Koss CA; Jin C; Phung N; Horng H; Sohn AH; Gandhi M
J Acquir Immune Defic Syndr; 2017 Dec; 76(4):367-371. PubMed ID: 28825944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
